Medexus Pharma is a rare disease pharmaceutical company focusing on therapeutic areas of rheumatology and auto-immune conditions.
Medexus Pharma has raised $26.0M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in November 2025.
Medexus Pharma's investors include MidCap Financial, Lumira Ventures.
Medexus Pharma is headquartered in Chicago, United States.
Medexus Pharma is a rare disease pharmaceutical company focusing on therapeutic areas of rheumatology and auto-immune conditions.
Medexus Pharma is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Medexus Pharma — Funding & Investors." VCBacked, November 17, 2025, https://www.vcbacked.co/company/medexus-pharma. Accessed August 14, 2026.
VCBacked. (2025). Medexus Pharma — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/medexus-pharma
{{cite web |title=Medexus Pharma — Funding & Investors |url=https://www.vcbacked.co/company/medexus-pharma |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated